McKesson Corporation
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of McKesson Corporation (MCK). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| North American Pharmaceutical | – | – | – | $261.37B 84.9% | $304.51B 85.1% · +16.5% | $336.65B 83.7% · +10.6% |
| Oncology & Multispecialty | – | – | – | $30.49B 9.9% | $36.86B 10.3% · +20.9% | $48.42B 12.0% · +31.4% |
| Medical-Surgical Solutions | $10.10B 4.2% | $11.61B 4.4% · +14.9% | $11.11B 4.0% · -4.3% | $11.31B 3.7% · +1.8% | $11.38B 3.2% · +0.6% | $11.51B 2.9% · +1.1% |
| Prescription Technology Solutions | $2.89B 1.2% | $3.86B 1.5% · +33.7% | $4.39B 1.6% · +13.5% | $4.77B 1.5% · +8.7% | $5.22B 1.5% · +9.4% | $5.81B 1.4% · +11.3% |
| International | $35.97B 15.1% | $36.35B 13.8% · +1.1% | $20.60B 7.4% · -43.3% | – | – | – |
| U.S. Pharmaceutical | $189.27B 79.5% | $212.15B 80.4% · +12.1% | $240.62B 87.0% · +13.4% | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.